Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Cholecystokinin A receptor | Starlite/ChEMBL | References |
Mus musculus | cholecystokinin B receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | sulfakinin receptor protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | adenosylhomocysteinase | 0.0393 | 1 | 0.5 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.0393 | 1 | 1 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.0393 | 1 | 0.5 |
Plasmodium vivax | adenosylhomocysteinase(S-adenosyl-L-homocystein e hydrolase), putative | 0.0393 | 1 | 0.5 |
Toxoplasma gondii | adenosylhomocysteinase, putative | 0.0393 | 1 | 0.5 |
Loa Loa (eye worm) | adenosylhomocysteinase | 0.0393 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0182 | 0.042 | 0.042 |
Plasmodium falciparum | adenosylhomocysteinase | 0.0393 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable adenosylhomocysteinase SahH (S-adenosyl-L-homocysteine hydrolase) (adohcyase) | 0.0393 | 1 | 0.5 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.0263 | 0.4087 | 0.0117 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.0393 | 1 | 1 |
Trypanosoma brucei | S-adenosylhomocysteine hydrolase, putative | 0.0393 | 1 | 0.5 |
Entamoeba histolytica | adenosylhomocysteinase, putative | 0.0393 | 1 | 0.5 |
Toxoplasma gondii | S-Adenosyl homocysteine hydrolase | 0.0393 | 1 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0393 | 1 | 1 |
Brugia malayi | O-Glycosyl hydrolase family 30 protein | 0.0263 | 0.4087 | 0.0117 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.0393 | 1 | 0.5 |
Mycobacterium ulcerans | S-adenosyl-L-homocysteine hydrolase | 0.0393 | 1 | 0.5 |
Mycobacterium leprae | putative S-adenosyl-L-homocysteine hydrolase SahH | 0.0393 | 1 | 0.5 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.0172 | 0 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Leishmania major | S-adenosylhomocysteine hydrolase | 0.0393 | 1 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.4087 | 0.4087 |
Echinococcus granulosus | adenosylhomocysteinase | 0.0393 | 1 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0182 | 0.042 | 0.042 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1250 nM | Inhibition of [125I]-CCK-8 binding to cholecystokinin type B receptor in the mouse cerebral cortex | ChEMBL. | 1573640 |
IC50 (binding) | = 1250 nM | Inhibition of [125I]-CCK-8 binding to cholecystokinin type B receptor in the mouse cerebral cortex | ChEMBL. | 1573640 |
IC50 (binding) | = 11500 nM | Inhibition of [125I]-CCK-8 binding to Cholecystokinin type A receptor in the rat pancreas | ChEMBL. | 1573640 |
IC50 (binding) | = 11500 nM | Inhibition of [125I]-CCK-8 binding to Cholecystokinin type A receptor in the rat pancreas | ChEMBL. | 1573640 |
Ratio (binding) | = 0.11 | Selectivity ratio defined as the ratio of IC50(CCK-A)/IC50(CCK-B) | ChEMBL. | 1573640 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.